International Journal of Medical and Dental Sciences

Permanent URI for this collection

https://imsear.searo.who.int/handle/123456789/149627

Editor : Dr. Sukhbir Sodhi

ISSN: 2454-8952(Print), 2320-1118 (E-Print)

Frequency: 2 issues a year

Language: English

Double blind peer reviewed journal

Web site: https://ijmds.org/

Browse

Browsing International Journal of Medical and Dental Sciences by Subject "acinetobacter"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    In vitro susceptibility pattern of Tigecycline against MRSA, ESBL producing Escherichia coli, Klebsiella species and Acinetobacter isolates in a rural tertiary care hospital.
    (2015-01) Nandi, P; Kumar, S; Biswas, T; Mitra, G; Chejara, SK; Roy, S
    Background: Tigecycline is the first commercially available glycycline, derivatives of the tetracycline antibiotics, having enhanced activity against various pathogens. In vitro activity has been demonstrated against multi drug resistant Gram positive and Gram negative pathogens like MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter Objective: To determine Tigecycline in vitro susceptibility pattern in MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter spp. Material and Methods: Investigations were carried out from August 2012-January 2014 to detect MRSA,ESBL producing Escherichia coli and Klebsiella spp. as well as Acinetobacter spp. by using a standard protocols and Tigecycline in-vitro susceptibility testing was done by Kirby Bauer Disc diffusion method and it’s MIC value against resistant isolates was evaluated.Statistical analysis was done by Fishers extract method. Result: Out of 107 Staphylococcus aureus isolates 52(48.59%) were MRSA, none of them showed resistance to Tigecycline. Out of 82 Esch.coli isolates 14 (i.e 17.07%) were ESBL producers, none of them showed resistance to Tigecycline.Out of 67 Klebsiella isolates 21 (i.e 31.34%) were ESBL producers out of which only 1 (i.e 4.76%) was resistant to Tigecycline.Out of 19 Acinetobacter spp.isolated 3 (i.e 15.78%) were resistant to Tigecycline. The MIC range for ESBL producing Eschcoli, Klebsiella spp., MRSA and acinetobacter spp were 0.14-0.45 μg/ml,0.25-2.4 μg/ml,0.12-0.26 μg/ml, 1-3.2 μg/ml respectively. Conclusion: The results of the study confirm the excellent in vitro activity of Tigecycline against Gram positive and Gram negative multidrug resistant pathogens.